半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展
朱秋艳, 薛岑 . 半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展[J]. 内科理论与实践, 2022 , 17(01) : 102 -106 . DOI: 10.16138/j.1673-6087.2022.01.020
| [1] | 李正欢, 张晓云, 陈杨, 等. 2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读(一)——稳定期药物管理[J]. 中国全科医学, 2021, 24(8): 923-929. |
| [2] | Telo S, Kuluöztürk M, Deveci F, et al. Serum cystatin C levels in COPD: potential diagnostic value and relation between respiratory functions[J]. J Med Biochem, 2018, 37(4): 434-440. |
| [3] | Chai L, Feng W, Zhai C, et al. The association between cystatin C and COPD: a meta-analysis and systematic review[J] .BMC Pulm Med, 2020, 20(1): 182. |
| [4] | Formiga MF, Vital I, Urdaneta G, et al. Higher serum levels of systemic inflammatory markers are linked to greater inspiratory muscle dysfunction in COPD[J]. Clin Respir J, 2019, 13(4): 247-255. |
| [5] | 赖雯, 吴东, 黄丹, 等. 血清胱抑素C对慢性阻塞性肺疾病急性加重风险的诊断价值[J]. 广东医科大学学报, 2020, 38(3):283-286. |
| [6] | Amado CA, García-Unzueta MT, Lavin BA, et al. The ratio serum creatinine/serum cystatin C (a surrogate marker of muscle mass) as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients[J]. Respiration, 2019, 97(4): 302-309. |
| [7] | Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J]. Clin Nutr, 2021, 40(3): 1274-1280. |
| [8] | Hu G, Wu Y, Zhou Y, et al. Cystatin C as a predictor of in-hospital mortality after exacerbation of COPD[J]. Respir Care, 2016, 61(7): 950-957. |
| [9] | 崔顺顺, 杨瑞青. 慢性阻塞性肺疾病合并肺动脉高压患者血清Cys-C水平变化及意义[J]. 临床肺科杂志, 2018, 23(1): 32-34. |
| [10] | 陈玉群, 肖叶, 胡大碧, 等. 血清同型半胱氨酸、胱抑素C水平对COPD合并呼吸衰竭患者预后的影响[J]. 中国煤炭工业医学杂志, 2020, 23(3): 293-298. |
| [11] | 邓正旭, 陈红, 文艳梅, 等. COPD患者血清胱抑素C、NT-proBNP、尿酸水平与病情严重程度及心脏受累的相关性分析[J]. 标记免疫分析与临床, 2020, 27(3): 471-475. |
| [12] | Yoshizawa T, Okada K, Furuichi S, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels[J]. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1283-1289. |
| [13] | Chen D, Cao C, Jiang L, et al. Serum cystatin C: a potential predictor for hospital-acquired acute kidney injury in patients with acute exacerbation of COPD[J]. Chron Respir Dis, 2020, 17(11): 1479973120940677. |
| [14] | Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea[J]. JAMA, 2020, 323(14): 1389-1400. |
| [15] | Voulgaris A, Archontogeorgis K, Nena E, et al. Serum levels of NGAL and cystatin C as markers of early kidney dysfunction in patients with obstructive sleep apnea syndrome[J]. Sleep Breath, 2019, 23(1): 161-169. |
| [16] | Chuang LP, Lin SW, Lee LA, et al. Elevated serum markers of acute kidney injury in patients with obstructive sleep apnea[J]. J Clin Sleep Med, 2019, 15(2): 207-213. |
| [17] | Chen DD, Huang JF, Huang SP, et al. Association of serum adiponectin level with cystatin C in male patients with obstructive sleep apnea syndrome[J]. Sleep Breath, 2020, 24(3): 953-960. |
| [18] | Liu T, Zhan Y, Wang Y, et al. Obstructive sleep apnea syndrome and risk of renal impairment: a systematic review and meta-analysis with trial sequential analysis[J]. Sleep Breath, 2021, 25(1): 17-27. |
| [19] | Nowiński A, Czyzak-Gradkowska A, Jonczak L, et al. Glomerular filtration rate in patients with obstructive sleep apnea: the influence of cystatin-C-based estimations and comorbidity[J]. J Thorac Dis, 2020, 12(3): 175-183. |
| [20] | Zhang XB, Jiang XT, Lin QC, et al. Effect of continuous positive airway pressure on serum cystatin C among obstructive sleep apnea syndrome patients[J]. Int Urol Nephrol, 2014, 46(10): 1997-2002. |
| [21] | Menou A, Duitman J, Crestani B. The impaired proteases and anti-proteases balance in idiopathic pulmonary fibrosis[J] .Matrix Biol, 2018, 68-69: 382-403. |
| [22] | Kasabova M, Joulin-Giet A, Lecaille F, et al. Regulation of TGF-β1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystatin C[J]. J Biol Chem, 2014, 289(23): 16239-16251. |
| [23] | Kasabova M, Villeret B, Gombault A, et al. Discordance in cathepsin B and cystatin C expressions in bronchoalveolar fluids between murine bleomycin-induced fibrosis and human idiopathic fibrosis[J]. Respir Res, 2016, 17(1): 118. |
| [24] | Zhang D, Huang C, Yang C, et al. Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts[J]. Respir Res, 2011, 12(1): 154. |
| [25] | Saidi A, Kasabova M, Vanderlynden L, et al. Curcumin inhibits the TGF-β1-dependent differentiation of lung fibroblasts via PPARγ-driven upregulation of cathepsins B and L[J]. Sci Rep, 2019, 9(1): 491. |
| [26] | Kim YI, Shin HW, Chun YS, et al. Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis[J]. Cell Death Dis, 2018, 9(5): 506. |
| [27] | Lee YT, Chen SC, Shyu LY, et al. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia[J]. Clin Chim Acta, 2012, 413(5-6): 630-635. |
| [28] | 卞韬, 谭明旗. 胱抑素C评估社区获得性肺炎严重程度的临床研究[J]. 中国基层医药, 2019, 26(13): 1566-1569. |
| [29] | 杨婷, 曾子鉴, 申永春, 等. 胱抑素C评估社区获得性肺炎患者严重程度及预测住院期间死亡概率的临床研究[J]. 华西医学, 2018, 33(1): 28-31. |
| [30] | 芦烨, 陈愉, 赵立. 多种生物标志物与社区获得性肺炎严重程度的相关性分析[J]. 国际呼吸杂志, 2020, 40(19): 1486-1490. |
| [31] | 张雨婷, 韩旭. 胱抑素C预测重症肺炎的价值分析[J]. 中国基层医药, 2019, 26(17):2075-2078. |
| [32] | 候茜, 宁沛雯. 血清IL-18与胱抑素C在社区获得性肺炎伴发急性肾损伤中的诊断价值[J]. 检验医学与临床, 2017, 11(14): 76-77. |
| [33] | Abdelaal NA, Shalaby SA, Khashana AK, et al. Serum cystatin C as an earlier predictor of acute kidney injury than serum creatinine in preterm neonates with respiratory distress syndrome[J]. Scand J Clin Lab Invest, 2017, 28(5): 1003-1014. |
| [34] | El-Gammacy TM, Shinkar DM, Mohamed NR, et al. Serum cystatin C as an early predictor of acute kidney injury in preterm neonates with respiratory distress syndrome[J]. Scand J Clin Lab Invest, 2018, 78(5): 352-357. |
| [35] | Hendrickson CM, Kwong YD, Belzer AG, et al. Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy[J]. Crit Care, 2020, 24(1): 416. |
| [36] | Kostrubiec M, Łabyk A, Pedowska-Włoszek J, et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism[J]. Heart, 2012, 98(16): 1221-1228. |
| [37] | Tutar N, Kemik NA, Yılmaz I, et al. Is serum cystatin C a predictor of acute pulmonary thromboembolism in patients with normal renal function?[J]. Clin Appl Thromb Hemost, 2015, 21(6): 533-538. |
| [38] | Leto G, Crescimanno M, Flandina C. On the role of cystatin C in cancer progression[J]. Life Sci, 2018, 202: 152-160. |
| [39] | Breznik B, Mitrović A, T Lah T, et al. Cystatins in cancer progression: more than just cathepsin inhibitors[J]. Biochimie, 2019, 166: 233-250. |
| [40] | Naumnik W, Niklińska W, Ossolińska M, et al. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy[J]. Folia Histochem Cytobiol, 2009, 47(2): 207-213. |
| [41] | Ohara G, Miyazaki K, Kurishima K, et al. Serum levels of cystatin C in elderly lung cancer patients[J]. Oncol Lett, 2012, 3(2): 303-306. |
| [42] | 张学德, 侯彦丽, 牛泽群, 等. 检测肺癌患者血清Cathepsin X及Cystatin C的临床意义[J]. 中国肺癌杂志, 2013, 16(8): 411-416. |
| [43] | 杨燕君, 董跃华, 王大伟, 等. 非小细胞肺癌患者血清胱抑素C及同型半胱氨酸的表达水平及其与淋巴结转移的相关性[J]. 中国老年学杂志, 2019, 39(17): 4189-4190. |
| [44] | Wang H, Shan D, Dong Y, et al. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer[J]. Oncol Lett, 2021, 21(1): 73. |
| [45] | 熊胜春, 吴静, 井洪家, 等. 胱抑素C及β2-微球蛋白中性粒细胞明胶酶相关脂质运载蛋白联合检测在肺癌患者化疗相关肾损伤早期检测中的作用[J]. 中华老年医学杂志, 2018, 37(10): 1107-1110. |
/
| 〈 |
|
〉 |
